These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 8871619)

  • 21. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
    Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
    Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity.
    Smythe JA; Fink PD; Logan GJ; Lees J; Rowe PB; Alexander IE
    J Immunol; 1999 Sep; 163(6):3239-49. PubMed ID: 10477593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B7-2 requirement for helminth-induced granuloma formation and CD4 type 2 T helper cell cytokine expression.
    Subramanian G; Kazura JW; Pearlman E; Jia X; Malhotra I; King CL
    J Immunol; 1997 Jun; 158(12):5914-20. PubMed ID: 9190944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
    Via CS; Rus V; Nguyen P; Linsley P; Gause WC
    J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
    Habib-Agahi M; Phan TT; Searle PF
    Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blockade of CD80 and CD86 at the time of implantation inhibits maternal rejection to the allogeneic fetus in abortion-prone matings.
    Jin LP; Zhou YH; Wang MY; Zhu XY; Li DJ
    J Reprod Immunol; 2005 Apr; 65(2):133-46. PubMed ID: 15811518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of cell cycle progression by CTLA4-CD80/CD86 interactions on CD4+ T cells depends on strength of the CD3 signal: critical role for IL-2.
    Mukherjee S; Ahmed A; Malu S; Nandi D
    J Leukoc Biol; 2006 Jul; 80(1):66-74. PubMed ID: 16624934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A.
    Mukherjee S; Ahmed A; Nandi D
    J Leukoc Biol; 2005 Jul; 78(1):144-57. PubMed ID: 15788440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28.
    Saito K; Sakurai J; Ohata J; Kohsaka T; Hashimoto H; Okumura K; Abe R; Azuma M
    J Immunol; 1998 May; 160(9):4225-31. PubMed ID: 9574523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+ and CD8+ T cells.
    Deeths MJ; Mescher MF
    Eur J Immunol; 1997 Mar; 27(3):598-608. PubMed ID: 9079798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells.
    Plumas J; Chaperot L; Jacob MC; Molens JP; Giroux C; Sotto JJ; Bensa JC
    Eur J Immunol; 1995 Dec; 25(12):3332-41. PubMed ID: 8566020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
    Gajewski TF
    J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis.
    Racke MK; Scott DE; Quigley L; Gray GS; Abe R; June CH; Perrin PJ
    J Clin Invest; 1995 Nov; 96(5):2195-203. PubMed ID: 7593605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of lethal graft-vs.-host disease by a single low dose injection of anti-T cell monoclonal antibody to the allograft recipients.
    Knulst AC; Bril-Bazuin C; Benner R
    Eur J Immunol; 1991 Jan; 21(1):103-7. PubMed ID: 1671355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulatory T cells modulate postischemic neovascularization.
    Zouggari Y; Ait-Oufella H; Waeckel L; Vilar J; Loinard C; Cochain C; Récalde A; Duriez M; Levy BI; Lutgens E; Mallat Z; Silvestre JS
    Circulation; 2009 Oct; 120(14):1415-25. PubMed ID: 19770391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.